Publicité
Publicité

BBOT

BBOT logo

BridgeBio Oncology Therapeutics, Inc. Common Stock

13.28
USD
Sponsorisé
-0.02
-0.17%
09 janv., 15:59 UTC -5
Fermé
exchange

Après-marché

13.09

-0.19
-1.45%

BBOT Rapports sur les bénéfices

Ratio de surprise positive

BBOT a dépassé 0 des 1 dernières estimations.

%

Prochain rapport

Date du prochain rapport
03 mars 2026
Estimate for Q4 25 (Revenue/ EPS)
--
/
-$0.54
Variation implicite de Q3 25 (Revenue/ EPS)
--
/
-47.57%
Variation implicite de Q4 24 (Revenue/ EPS)
--
/
--

BridgeBio Oncology Therapeutics, Inc. Common Stock earnings per share and revenue

On 12 nov. 2025, BBOT reported earnings of -1.03 USD per share (EPS) for Q3 25, missing the estimate of -0.39 USD, resulting in a -159.05% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -1.98% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 9 analystes forecast an EPS of -0.54 USD, with revenue projected to reach -- USD, implying an baisse of -47.57% EPS, and hausse of 0.00% in Revenue from the last quarter.
FAQ
For Q3 2025, BridgeBio Oncology Therapeutics, Inc. Common Stock reported EPS of -$1.03, missing estimates by -159.05%, and revenue of $0.00, 0% as expectations.
The stock price moved down -1.98%, changed from $12.63 before the earnings release to $12.38 the day after.
The next earning report is scheduled for 03 mars 2026.
Based on 9 analystes, BridgeBio Oncology Therapeutics, Inc. Common Stock is expected to report EPS of -$0.54 and revenue of -- for Q4 2025.
Chèque FXEmpire's Earnings Calendar for today's list of reporting companies.
Publicité